title: Arachidonic acid metabolism by nuclei of a retinoic acid--or vitamin D3-differentiated human leukemia cell line HL-60.
abstract: Arachidonic acid (AA) metabolism in nuclei of human pro-myelocytic leukemia (HL-60) cells was investigated during retinoic acid (RA)-induced granulocytic differentiation and 1 alpha, 25 dihydroxy-vitamin D3-induced monocytic differentiation. The whole control HL-60 cells and their nuclei hardly converted [1-14C]-AA to any metabolites comigrating with authentic prostaglandins (PGs). On the other hand, RA-treated HL-60 cells acquired the ability to convert [1-14C]-AA to PGE2 predominantly and thromboxane B2 (TXB2) to a small degree, whereas the nuclei of the differentiated cells acquired the ability to convert predominantly to TXB2. In contrast, 1 alpha, 25-dihydroxy-vitamin D3-treated HL-60 cells acquired the ability to convert [1-14C]-AA to PGE2, PGF2 alpha, TXB2 and 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT), whereas the nuclei of the differentiated cells acquired the ability to convert to PGF2 alpha, TXB2 and HHT. The significance of the acquisition of cyclooxygenase and TX synthetase by the nucleus is unclear, but there may be a specific relationship between the specific PGs formed by the nuclear membrane and nuclear events during HL-60 cell differentiation.
authors.affiliation: 2nd Department of Orthodontics, Faculty of Dentistry, Tokyo Medical and Dental University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsumoto
authors.forename: I
authors.initials: I
authors.lastname: Morita
authors.forename: S
authors.initials: S
authors.lastname: Murota
mesh_terms: D016718:Arachidonic Acid / Q000378:metabolism*; D002117:Calcitriol / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D015237:Dinoprost / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D005231:Fatty Acids, Unsaturated / Q000096:biosynthesis; D006098:Granulocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism* / Q000473:pathology; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013929:Thromboxane B2 / Q000096:biosynthesis; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
chemical_list: D005231:Fatty Acids, Unsaturated; D016718:Arachidonic Acid; C008033:12-hydroxy-5,8,10-heptadecatrienoic acid; D013929:Thromboxane B2; D014212:Tretinoin; D015237:Dinoprost; D002117:Calcitriol; D015232:Dinoprostone